GlassScriptPhysician profile
Jennifer H Davisson
NPI 1114024668
$342,879.64
in general payments reported to CMS, 2019-2025
38 companies · $96K in 2025
The $96K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $10K · 2022: $36K · 2023: $86K · 2024: $115K · 2025: $96K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $126K · Consulting Fee: $86K · Travel and Lodging: $64K · Food and Beverage: $21K · Education: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $125,623.26 |
| Consulting Fee | $85,939.39 |
| Travel and Lodging | $63,987.66 |
| Food and Beverage | $20,828.89 |
| Education | $282.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $150,603.94 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $111,992.34 | 2023-2025 | Zoryve |
| Incyte Corporation | $27,627.96 | 2021-2025 | Opzelura, Opzelura |
| Almirall LLC | $11,455.67 | 2021-2025 | Klisyri, Seysara |
| Leo Pharma INC. | $11,016.82 | 2021-2025 | Adbry, Anzupgo |
| Verrica Pharmaceuticals INC. | $7,147.66 | 2023-2024 | Ycanth |
| Kowa Pharmaceuticals America, INC. | $5,057.88 | 2025 | Zoryve |
| Journey Medical Corporation | $3,779.29 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,602.99 | 2021-2025 | Winlevi, Ilumya, Blu-U |
| E.R. Squibb & Sons, L.L.C. | $1,496.87 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $1,436.99 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Janssen Biotech, INC. | $1,302.44 | 2021-2025 | Tremfya |
| Dermavant Sciences, INC. | $1,099.51 | 2022-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $1,072.32 | 2021-2025 | |
| Ucb, INC. | $976.68 | 2021-2025 | Bimzelx, Cimzia |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Davisson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.